The FDB OptimiseRx Strategy for 2018

FDB OptimiseRx is the leading medicines optimisation solution in primary care in the UK. More than 120 Clinical Commissioning Groups (CCGs) and Health Boards benefit from FDB OptimiseRx patient-specific medicines guidance across 5000 GP practices.

  • Reaching 1,000,000 prescribing transactions a day at peak times
  • Saving the NHS £44.53 million
  • With 21.5 % of messages accepted and prescribing interactions acted upon

To build on this, we have released our strategy for 2018, that outlines our strategic direction and highlights case studies from CCGs. Read the FDB OptimiseRx Strategy 2018 to find out how we are helping your healthcare community to meet your medicines optimisation goals through safe, high-quality and cost-effective prescribing.:

In the FDB OptimiseRx Strategy 2018, Darren Nichols, Managing Director at FDB comments: “We have been privileged to work with more than 117 NHS organisations in England and Wales in 2017 – a 50% increase on 2016. FDB OptimiseRx has gone from strength to strength in the past year. Our company has grown, and we have appointed new leaders, bringing with them a fresh approach to medicines technology and leadership qualities that will help drive our company forward in 2018.

This year, the number of prescribing transactions that FDB OptimiseRx supports reached 1 million hits a day at peak times. To reflect this major milestone, we have overhauled our infrastructure to allow us to more powerfully process data. The new data infrastructure has enabled us to build more tools for medicines management teams such as customisation and audit tools and to deliver new reports and metrics. In 2018, we will be building on these developments to further enhance the solution and the service that we provide to our customers.”

To read some of our CCG customer case studies and find out more about our plans for 2018 – download the FDB OptimiseRx Strategy here.

For more solution information please visit FDB OptimiseRx or to request a demonstration, please contact us.